Havel R, Kane J: Introduction: structure and metabolism of plasma lipoproteins. The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et ai, Eds. McGraw-Hill Book Co, New York, 2001, p 2705

Brunzell JD, Chait A, Biennan EL: Pathophysiology of lipoprotein transport. Metabolism 27:1109, 1978

Brunzell JD, Albers JJ, Chait A, et al: Plasma lipoproteins in familial combined hy­perlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 24:147, 1983

Kanep, Havel RJ: Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. Scriver CR, Beaudet AL, Sly WS, et aI, Ed •. McGraw-Hill Book Co, New York, 2001

Utermann G: Lipoprotein (a). The Metabolic and Molecular Bases of Inherited Disease, 8th ed. Scriver CS, Beaudet AL, Sly WS, et aI, Eds. McGraw-Hill Book Co, New York, 2001, p 2753

Brumell J, Oeeb 5: Familial lipoprotein lipase deficiency, apo cn deficiency, and hepatic lipase deficiency. The Metabolic and Molecular Bases of Inherited Disease, 8th cd., Vol 2. Scriver CR, Beaudet AL, Sly WS, et ai, Eds. McGraw-Hill Book Co, New York, 2001, p 2789

Mahley R, Rall S: Type III hyperlipoproteinemia (dysbetalipoproteinemia): the roie of apolipoprotein E in normal and abnormal lipoprotein metabolism. The Metabolic and Molecular Bases of lnherited Disease, 8th ed. Scriver CR, Beaudet AL, Sly WS, et aI, Eds. McGraw-Hill Book Co, New York, 2001, p 2835

Goldstein JL, Hobbs H, Brown MS: Familial hypercholesterolemia. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. Scriver CS, Beaudet AL, Sly WS, et ai, Eds. McGraw-Hill Book Co, New York, 2001, p 2863

Tan A, Breslow J, Rubin E: Genetic disorders affecting plasma high-density lipoproteins. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. Scriver CS, Beaudet AL, Sly WS, et al, Eds. McGraw-Hill Book Co, New York, 2001, p 2915

Deeb SS, Zambon A, Carr MC, et al: Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 44:1279, 2003

Frikke Schmidt R, Nordestgaard BG, Jensen GB, et al: Genetic variation in ABC transporter Al contributes to HDL cholesterol in the general population. J Clin Invest 114:1343,2004

Carr MC, Brunzell JD: Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coro· nary artery disease risk. J Clin Endocrinol Metab 89:2601, 2004

Griffin BA: Lipoprotein atherogenicity: an overview of current mechanlsms. Proc Nutr Sac 58:163, 1999
p>Steinberg D, Pearson T A, Kuller LH: Alcohol and atherosclerosis. Ann Intern Med 114:967,1991

Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel In). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 285:2486, 2001

Brown CD, Higgins M, Donato KA, et al: Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 8:605, 2000

Austin MA, McKnight B, Edwards KL, et al: Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 101:2777, 2000

Knopp RH: Drug treatment oflipid disorders. N Engl J Med 341:498, 1999

Rubins HB, Robins J, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. NEnglJ Med 341:410, 1999

Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231:360, 1975

Carr MC: The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88:2404, 2003

Lemieux S, Despres JP, Moorjani 5, et al: Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue? Diabetologia 37:757, 1994

Nieves D, Cnop M, Retzlaff B, et al: The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 52:172, 2003

Purnell JQ, Kahn SE, Albers IT, et al: Effect of weight loss with reduction of intra-ab­dominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 85:977, 2000

Grundy SM: Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J CardioI90:l1i, 2002

Cefalu WT, Wang ZQ, Werbel S, et a1: Contribution of visceral fat mass to the in· sulin resistance of aging. Metabolism 44:954, 1995

Bermudez aI, Tucker KL: Total and central obesity among elderly Hispanics and the association with type 2 diabetes. Obes Res 9:443, 2001

Lempiainen P, Mykkanen L, Pyorala K, et a1: Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 100:123, 1999

Mykkanen L, Kuusisto J, Haffner SM, et a1: Hyperinsulinemia predicts multiple atherogenic changes in lipoproteins in elderly subjects. Arteriosder Thromb 14:518; 1994

Cefalu WT, Werbel SI Bell-Farrow AD, et al: Insulin resistance and fat patterning with aging: relationship to metabolic risk factors for cardiovascular disease. Metabolism 47:401,1998

Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 106:453, 2000

Ford E, Giles W, Dietz W: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356,2002

Alexander CM, Landsman PB, Teutsch SM, et al: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES ill participants age 50 years and older. Diabetes 52:1210, 2003

Lamarche B, Moorjani S, Cantin B, et al: Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Arteriosc1er Thromb Vase BioI 17:1098, 1997 35. Williams RR, Hopkins PN, Hunt SC, et al: Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med 150:582, 1990 36. Goldstein JL, Hazzard WR, Schrott HG, et al: Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 52:1533, 1973

Goldstein JL, Schrott HG, Hazzard WR, et al: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544, 1973

Hazzard WR, GoldsteinJL, Schrott MG, et al: Hyperlipidemia in coronary heart disease. III. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarctton. J Clin Invest 52:1569,1973

A yyobi AF, McGladdery SH, McNeely MJ, et al: Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vase BioI 23:1289, 2003

Jarvik GP, Brunzell JD, Austin MA, et al: Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. ArteriosclerThromb 14:1687, 1994

Austin MA, Horowitz H, Wijsman E, et al: Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia. Atherosclerosis 92:67, 1992

Babirak SP, Brown BG, Bmnzell JD, et al: Familial combined hyperlipidemia and abnonnallipoprotein lipase. ArteriosclerThromb 12:1176, 1992

Purnell JQ, Kahn SE, Schwartz RS, et al: Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc BioI 21:567, 2001

Brown G, Albers JJ, Fisher LD, et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1289, 1990

Calhoun HM, Betteridge DJ, Durrington PN, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo controlled trial. Lancet 364:685,2004

Marks D, Thorogood M, Neil HA, et al: A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168:1, 2003

Grundy SM, Vega GL, McGovern ME: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch lntern Med 162:1568,2002

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273:199, 1995

Anderson GL, Limacher M, Assaf AR, et al: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAM A 291:1701, 2004

Joven J, Villabona C, VUella E, et al: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579, 1990

Samuelsson O, Altman PO, Knight-Gibson C. et al: Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Nephron 75:286, 1997

Khovidhunkit W, Memon RA, Feingold KR, et al: Infection and inflammation-in~ duced proatherogenic changes of lipoproteins. J Infect Dis 181:5462, 2000

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251:351, 1984

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365, 1984

Frick MH, Elo 0, Haapa K, et al: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237, 1987

Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N EnglJ Med 333:1301, 1995

Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. Am J CardioI79:756, 1997

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440, 1998

Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615, 1998

Gotto AM Jr, Boccuzzi S, Cook JR, et al: Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. Am J Cardiol 86:1176,2000

Sever PS, Dahlof B, Poulter NR, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Low­ering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149, 2003

Pekkanen J, Linn S, Heiss C,et al: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N EnglJ Med 322:1700, 1990

Watts GF, Lewis B, Brunt]N, et al: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339:563,1992

de Lorgeril M, Salen P, Martin JL, et al: Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease: insights Into the cardioprotective effect of certain nutriments. J Am Coli CardioI28:1103, 1996

de Lorgeril M, Salen PI MartinJL, et al: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99:779, 1999

Zambon A, Hokanson JE, Brown BG, et at: Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99:1959, 1999

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). Lancet 344:1383,1994

Pedersen TR, Olsson AC, Faergeman О, et al: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97:1453, 1998

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349,1998

Simes RJ, Marschner IC, Hunt D, et al: Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LWID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 05:1162, 2002

Sacks FM, Pfeffer MA, Moye LAI et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001, 1996

Sacks FM, Moye LAI Davis BR, et al: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 97:1446, 1998

MCR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet 360:7, 2002

Cannon CP, Braunwald E, McCabe CH, et al: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495, 2004

Nissen SE, Tuzcu EM, Schoenhagen P, et al: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071, 2004

Brown BG, Zhao XQ, Chait A, et a1: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583, 2001

Snow V, Aronson MD, Hombake ER, et al: Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 140:644,2004

към началото